Richard Wooster PhD

Richard Wooster is President of R&D and Chief Scientific Officer at Tarveda Therapeutics. Previously he was Vice President and Discovery Performance Unit Head in Oncology at GlaxoSmithKline. During his academic career he discovered the breast cancer susceptibility gene BRCA2, and was one of the founders of the Cancer Genome Project at the Welcome Trust Sanger Institute where, among many achievements, mutations in BRAF were first discovered and he developed the COSMIC mutation database and web site.